My understanding of interim analyses and stopping rules is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
26 likes 8mo
Topic summary
Interim analyses and stopping rules
This is a generated summary. It shows the 5 most-liked posts from a topic of 30, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
Nobody has said the unglamorous part of interim analyses and stopping rules yet, so: most of the variation is explained by things that are boring to write about and easy to check.
27 likes 5mo
I had written a reply contradicting post #17 and deleted it. Here is what survived.
Absolute and relative effects answer different questions. Write down the event rate in each arm and the difference between them; everything quotable is derived from those two numbers.
19 likes 4mo
Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment), concealment (could randomisation be subverted), blinding (who was blinded and why or why not), completeness of outcome reporting.
It is one reading of the data and not the only reasonable one.
26 likes 2mo
Read the full topic (30 posts)
Promoted into the documentation commons. The content of this topic is maintained at SCALE — trial digest, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Adjudicated events and why the definition matters
On the subject in the title: Adjudicated events and why the definition matters Working notes rather than a conclusion. A follow-up question about adjudicated events that I did not know to ask the first time.…
|
2 | 4.5k | 2mo | |
|
Non-inferiority margins: how they are chosen and how they are abused
Posting this under the heading it deserves: Non-inferiority margins: how they are chosen and how they are abused Everything below is what sits behind that. A question about non-inferiority margins that I…
|
+42 | 46 | 10k | 5mo |
|
Composite endpoints and the component doing the work
Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about composite endpoints in one place, because…
|
+3 | 7 | 33k | 13h |
|
Primary endpoint hierarchies and why order matters — one year on
On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…
|
+56 | 61 | 37k | 11h |
|
Revisiting: Primary endpoint hierarchies and why order matters
Posting this under the heading it deserves: Revisiting: Primary endpoint hierarchies and why order matters Everything below is what sits behind that. I was wrong about Primary endpoint hierarchies in a thread…
|
+21 | 25 | 46k | 3mo |
Related topics — sharing the tags intention to treat, surrogate endpoints, open label
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first…
|
2 | 39k | 6mo | |
|
SNAC and the mechanism of oral peptide absorption — the long version
SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. Question about what the published evidence for this…
|
+32 | 36 | 6.8k | 16mo |
|
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset
Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…
|
+27 | 31 | 17k | 25d |
|
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on…
|
2 | 17k | 6h | |
|
Journal club: SURPASS-2 and the semaglutide 1 mg comparator
On the subject in the title: Journal club: SURPASS-2 and the semaglutide 1 mg comparator Working notes rather than a conclusion. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before posting;…
|
+71 | 76 | 52k | 21mo |